FDA Envisions Flexible Approach To Expanded Use Of Accelerated Approval
Executive Summary
In its desktop reference guidance on the four expedited regulatory pathways, FDA broadens its view of when an investigational drug fills an “unmet medical need” and guides sponsors through the use of intermediate clinical endpoints as a basis for accelerated approval.
You may also be interested in...
Redefining Accelerated Approval Criteria Would Expand Pathway’s Use, Panel Says
Expanding the definition of “unmet medical need” and adopting a narrow, molecularly targeted approach to determining the existence of “available therapies” would enable use of the approval pathway in earlier treatment settings, a group of stakeholders tells a cancer research conference.
FDA To Provide Expedited Approval Desktop Reference
Comprehensive guidance document is expected to describe FDASIA changes and clarify terms that have become confusing as more pathways emerge to speed drug approvals.
FDA Drug Shortage Strategy: Enforcement Discretion, Patient Public Relations
Rapid approval of a new, preservative-free generic methotrexate and permission to import an unapproved version of doxorubicin touted at press conference as FDA emphasizes the success of administrative efforts.